Chronic inflammation in Alzheimer's disease offers therapeutic opportunities

Expert Review of Neurotherapeutics

Volumn 1, Issue 1, 2001, Pages 53-60

  McGeer, Edith G ^a   McGeer, Patrick L ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Alzheimer's disease; Autotoxity; Chronic inflamation; Nonsteroidal anti inflamamatory drug

Indexed keywords

CYTOKINE; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT;

ALZHEIMER DISEASE; AMNESIA; CENTRAL NERVOUS SYSTEM; CHRONIC INFLAMMATION; CLINICAL TRIAL; COMPLEMENT SYSTEM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN TISSUE; INCINERATION; MICROGLIA; NERVE CELL NECROSIS; PHAGOCYTE; REVIEW;

EID: 0035741377     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.1.1.53     Document Type: Review

References (61)

1. Complement activation in amyloid plaques in Alzheimer's dementia
2. Immuno-electron-microscopic localization of complements in amyloid fibrils of senile plaques
3. Immune system response in Alzheimer's disease
4. Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease
5. Ultrastructural localization of complement membrane attack complex (MAC)-like immunoreactivity in brains of patients with Alzheimer's disease
6. Autotoxicity and Alzheimer's disease
7. Localization of sites through which C-reactive protein binds to and activates complement to residues 14-26 and 76- 92 of the human C1q A chain
8. Association of amyloid P component with complement proteins in neurologically diseased tissue
9. Serum amyloid P component binds to histones and activates the classical complement pathway
10. Complement activation by β-amyloid in Alzheimer's disease
11. Complement interactions with amyloid β 1-42: A nidus for inflammation in AD brains
12. El 'tercer elemento' de los centros nerviosos. Poder fagocitario y movilidad de la microglia
13. Brain microglia constitutively express β 2 integrins
14. Microglial cells around amyloid plaques in Alzheimer's disease express leucocyte adhesion molecules of the LFA- 1 family
15. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR
16. Expression of immune system-associated antigens by cells of the human central nervous system: Relationship to the pathology of Alzheimer's disease
17. Specific domains of β-amyloid from Alzheimer plaque elicit neurone killing in human microglia
18. Interaction of various intracellular signaling mechanisms involved in mononuclear phagocyte toxicity toward neuronal cells
19. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
20. Comparative analysis of Aβ chemical structure and amyloid plaque morphology of transgenic mice and Alzheimer's disease brains
21. Cytokine indices in Alzheimer's temporal cortex: No change in mature IL Jβ or IL-1 RA but increases in the associated acute phase proteins IL-6, α 2-macroglobulin and C-reactive protein
22. Brain interleukin-1 β in Alzheimer's disease and vascular dementia
23. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease
24. Brain interleukin-1 and S-100 immunoreactivity are elevated in Down's syndrome and Alzheimer's disease
25. Complement and cytokine gene expression in cultured microglia derived from postmortem human brains
26. Cytokine-gene expression in measles-infected adult human glial cells
27. Human astrocyte production of tumour necrosis factor-α, interleukin-1 β and interleukin-6 following exposure to lipopolysaccharide endotoxin
28. Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus
29. α-antichymotrypsin is associated solely with amyloid deposits containing the β-protein. Amyloid and cell localization of α1-antichymotrypsin
30. Interleukin-6 and α2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortex
31. α-2-macroglobulin is genetically associated with Alzheimer's disease
32. Association of a haplotype for tumor necrosis factor in siblings with late-onset Alzheimer's disease: The NIMH Alzheimer's disease genetics initiative
33. Association of an interleukin-1 α polymorphism with Alzheimer's disease
34. Association of early-onset Alzheimer's disease with an interleukin-1 α gene polymorphism
35. Genetic effect of α-1-antichymotrypsin on the risk of Alzheimer's disease
36. Polymorphisms of the IL-6 gene increase the risk for late onset Alzheimer's disease and affect IL-6 plasma levels
37. Gene polymorphism affecting α 1-antichymotrypsin and interleukin-1 plasma levels increases Alzheimer's disease risk
38. Association of interleukin-1 gene polymorphisms with Alzheimer's disease
39. A genetic variation of the inflammatory cytokine interleukin-6 delays the initial onset and reduces the risk for sporadic Alzheimer's disease
40. Confirmation of the genetic association of interleukin-1A with early onset sporadic Alzheimer's disease
41. Association between polymorphism in regulatory region of gene encoding tumour necrosis factor A and risk of Alzheimer's disease and vascular dementia: A case-control study
42. Apolipoprotein E: High avidity binding to β-amyloid and increased frequency of Type 4 allele in late-onset familial Alzheimer's disease
43. Polymorphisms in inflammatory genes enhance the risk of Alzheimer's disease
44. Serum amyloid P immunoreactivity in hippocampal tangles, plaques and vessels: Implications for leakage across the blood-brain barrier in Alzheimer's disease
45. Human neurons generate C-reactive protein and amyloid P: Upregulation in Alzheimer's disease
46. Upregulated production and activation of the complement system in Alzheimer's disease brain
47. Generation of C-reactive protein and complement components in atherosclerotic plaques
48. Human heart generates complement proteins that are upregulated and activated after myocardial infarction
49. Is aspirin underused in myocardial infarction?
50. The medical management of stroke
51. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiological studies
52. Risk of Aizheimer's disease and duration of NSAID use
53. Duration of non-steroidal anti-inflammatory drug use and risk of Alzheimer's disease. The Rotterdam study
54. Clinical trial of indomethacin in Alzheimer's disease
55. A double-blind, placebo-controlled trial of diclofenac misoprostol in Alzheimer's disease
56. Results of a double-blind, placebo-controlled study of Celebrid for the progression of Alzheimer's disease
57. Human serum amyloid P component oligomers bind and activate the classical complement pathway vis residues 14-26 and 76-92 of the A chain collagen-like region of C1q
58. Charge-based binding of complement component C1q to the Alzheimer amyloid β-peptide
59. Nitric oxide-releasing NSAIDs: A novel class of GI-sparing anti-inflammatory drugs
60. Prevalence of dementia amongst elderly Japanese with leprosy: Apparent effect of chronic drug therapy